Options for first-line cisplatin-eligible patients
|
|
|
- Jeffry Parrish
- 5 years ago
- Views:
Transcription
1
2 The Past
3 Options for first-line cisplatin-eligible patients Metastatic urothelial cancer Cisplatin-eligible Gemcitabine/ cisplatin MVAC or high-dose intensity MVAC Paclitaxel/ cisplatin/ gemcitabine Bellmunt et al. Ann Oncol 2014
4 OS (%) Median survival with gemcitabine/cisplatin and MVAC in fit patients is months Gemcitabine/cisplatin MVAC HR: 1.09 ( ); log-rank p=0.44, Wald s p= Time (months) von der Maase et al. J Clin Oncol 2005
5 OS (%) High-dose intensity MVAC is an alternative to MVAC MVAC HD-MVAC HR: 0.80 ( ) Log-rank p= EORTC (3.2 years) Time (years) 6 7 Sternberg et al. Eur J Cancer 2001
6 High-dose intensity MVAC is an alternative to MVAC Sternberg et al. Eur J Cancer 2001
7 OS (%) Paclitaxel/cisplatin/gemcitabine is an option for some 1L patients 100 EORTC Gemcitabine/cisplatin Paclitaxel/cisplatin/gemcitabine Overall log-rank test p= Time (years) 6 7 Exploratory analysis of patients with bladder as the primary tumour Median OS was significantly longer after paclitaxel/cisplatin/gemcitabine: 15.9 vs 11.9 months; HR=0.80 (95% CI: ), p=0.025 Bellmunt et al. J Clin Oncol 2012
8 Options for first-line cisplatin-ineligible patients Metastatic urothelial cancer Cisplatin-eligible Cisplatin-ineligible Gemcitabine/ cisplatin MVAC or high-dose intensity MVAC Paclitaxel/ cisplatin/ gemcitabine Carboplatin-based regimens or single agents: taxane, gemcitabine Bellmunt et al. Ann Oncol 2014
9 Median survival with gemcitabine/carboplatin and M-CAVI in unfit patients is <10 months De Santis et al. J Clin Oncol 2012
10 Options for second-line patients Metastatic urothelial cancer Cisplatin-eligible Cisplatin-ineligible Gemcitabine/ cisplatin MVAC or high-dose intensity MVAC Paclitaxel/ cisplatin/ gemcitabine Carboplatin-based regimens or single agents: taxane, gemcitabine Progression <12 months 2L chemotherapy 1.Vinflunine 2.Taxane-based 3.Clinical trial Progression >12 months 1. Platinum-based re-challenge Bellmunt et al. Ann Oncol 2014
11 OS (%) Median survival with second-line was <7 months OS in the eligible population* Vinflunine + BSC BSC HR=0.78 Log rank p= Time (months) Pal SK, et al. Plos One 2015 Bellmunt et al. J Clin Oncol 2009
12 Before 2016: substantial unmet medical need in the treatment of urothelial cancer 1. Bellmunt et al. Ann Oncol 2014; 2. von der Maase et al. J Clin Oncol 2005; 3. De Santis et al. J Clin Oncol Bellmunt et al. J Clin Oncol 2009; 5. von der Maase et al. J Clin Oncol 2000
13 The Present
14 Panorama regulatorio inmunoterapia FDA & EMA 1. Sternberg CN et al. Cancer 1989;64: ; 2. Roth BJ et al. J Clin Oncol 1994;12: ; 3. Eli Lilly. SmPC Gemzar 01 Jul Available at: 4. McCaffrey JA et al. J Clin Oncol 1997;15: ; 5. Von der Maase H et al. J Clin Oncol 2000;18: ; 6. Sternberg CN et al. J Clin Oncol 2001;19: ; 7. Meluch AA et al. J Clin Oncol 2001;19: ; 8. EMA. EMEA/CHMP/512295/2008; 24 Sep Available at: 9. Bellmunt J et al. J Clin Oncol 2009;27: ; 10. EMA. EMEA/H/C/000983; Available at: De Santis M et al. J Clin Oncol 2009;27: ; 12. Bellmunt J et al. J Clin Oncol 2012;30: ; 13. Rosenberg JE et al. Lancet 2016;387: ; 14. Massard C et al. ASCO Abstract #4502 and oral presentation; 15. AstraZeneca. Press release 17 Feb Available at: FDA. Press release 18 May Available at: Apolo AB et al. ASCO Abstract #4514 and poster; 18. Galsky MD et al. ESMO Abstract #LBA31_PR; 19. Balar A et al. ESMO Abstract #LBA32_PR; 20. FDA. Press release 2 Feb Available at FDA. Press release 9 May Available at All links accessed Sept 2017.
15 Role of immunotherapy in bladder cancer CD8 tumor-infiltrating lymphocytes are predictive of survival in MIUC Sharma et al. PNAS 2007
16 Immune Checkpoints inhibitors in platinum-refractory setting Atezolizumab Nivolumab Pembrolizumab Avelumab Durvalumab Phase Number of patients Phase II single arm & Phase III randomized Phase II single arm Phase III randomized Phase Ib Phase I/II Dosing 1200 mg q3w 3 mg/kg q3w 200 mg q3w 10 mg/kg q2w 10 mg/kg q2w ORR 15% (IC 2/3 23%) 19.6% 21.1% 16.1% 17.8% Duration of response Median OS 84% ongoing at median fu 11.7 months months 77% ongoing at median fu of 7 months 72% ongoing at median fu of 14.1 months 64% ongoing at data cut NR at data cut 8.7 months 10.3 months 7.7 months 18.2 months Median PFS 2.1 months 2.0 months 2.1 months 1.5 months 1.5 months Grade ¾ TRAEs 16% 20% 18% 13.5 % (15% G3) 10.8% G %
17 Powles T, et al. Nature 2014
18 IMvigor210 Cohort 2: study design Rosenberg, et al. Lancet 2016
19 Atezolizumab in muc: IMvigor 211 phase III Powles T, et al. ASCO GU 2018
20 Atezolizumab in muc: IMvigor 211 phase III Powles T, et al. ASCO GU 2018
21 Objective response (%) Atezolizumab in muc: IMvigor 211 phase III % of responses were ongoing with atezolizumab vs 21% with chemotherapy TECENTRIQ Chemotherapy 21.7 months 7.4 months Time (months) Powles T, et al. ASCO GU 2018
22 Pembrolizumab in muc: Keynote-045 phase III Bellmunt J, et al. ASCO GU 2018
23 Pembrolizumab in muc: Keynote-045 phase III Bellmunt J, et al. ASCO GU 2018
24 Patient s characteristics Bellmunt J, et al. ASCO GU 2018, Powles T, et al. ASCO 2018
25 PDL1 as a biomarker Sandy Srinivas. ASCO 2018
26 Inconsistencies in the biomarkers with the same drug and asssay!!! Powles T et al. ASCO GU 2018
27 Atezolizumab in muc: IMvigor 211 phase III Powles T, et al. ASCO GU 2018
28 Prognostic factors with IO second-line Pond G, et al. ASCO GU 2018
29 ImVigor 210 (cohort 1) Balar A, et al. Lancet 2017
30 ImVigor 210 (cohort 1) Balar A, et al. Lancet 2017
31 ImVigor 210 (cohort 1) Balar A, et al. Lancet 2017
32 Keynote-052 Castellano et al. EAU 2018
33 Keynote-052 Castellano et al. EAU 2018
34 What is the current paradigm? Kamat et al.j Immunother Cancer 2017
35
36 The Future
37 Molecular subtypes
38 Molecular subtypes
39 New drugs New indications
40 New drugs: Ramucirumab Nab-paclitaxel FGFR inhibitors Enfortumab New indications
41 Ramucirumab: RANGE phase III trial (PFS) Petrylak D, et al. ESMO 2017
42 Ramucirumab: RANGE phase III trial (PFS) Petrylak D, et al. ESMO 2017
43 Ramucirumab: RANGE phase III trial (PFS) Petrylak D, et al. ESMO 2017
44 Nab-paclitaxel: phase II trial Sridhar S, et al. ASCO 2018
45 Nab-paclitaxel: phase II trial Sridhar S, et al. ASCO 2018
46 FGFR biology Nicholas Turner & Richard Grose. Nat Rev Cancer 2010; 10:
47 FGFR inhibitors in advanced urothelial carcinoma Apolo A, ASCO 2018
48 FGFR inhibitors in advanced urothelial carcinoma Pal S, et al. Cancer Discov 2018; Joerger M, et al. ASCO GU 2018
49 Erdafatinib: BLC2001 phase II Siefker-Radtke et al. ASCO 2018
50 Erdafatinib: BLC2001 phase II Siefker-Radtke et al. ASCO 2018
51 Enfortumab Vedotin Rosenberg J, et al. ASCO 2018
52 Enfortumab Vedotin Rosenberg J, et al. ASCO 2018
53 New drugs: Ramucirumab Nab-paclitaxel FGFR inhibitors Enfortumab New indications First-line setting Neoadjuvant Adjuvant
54 What s coming up next in 1L? Phase III studies of immunotherapy ± chemotherapy IMvigor130 (NCT ) KEYNOTE-361 (NCT ) TECENTRIQ Pembrolizumab 1L, locally advanced / metastatic UC ECOG PS 0 2 N=1200 R TECENTRIQ + platinum/gemcitabine 1L unresectable or metastatic UC ECOG PS 2 N=990 R Pembrolizumab + platinum/gemcitabine Platinum/gemcitabine + placebo Platinum/gemcitabine + placebo Co-primary endpoints: PFS and OS Final data collection date for primary endpoint: December 2018 Current accrual status: recruiting Co-primary endpoints: PFS and OS Final data collection date for primary endpoint: January 2019 Current accrual status: recruiting ClinicalTrials.gov (NCT and NCT )
55 What s coming up next in 1L? Phase III studies of PD-L1/PD-1 inhibitors + anti-ctla4 DANUBE (NCT ) CheckMate 901 (NCT ) 1L unresectable stage IV UBC Eligible / ineligible for cisplatin-based CT N=1005 R Durvalumab Durvalumab + tremelimumab 1L unresectable or metastatic UC ECOG PS 2 N=897 R Nivolumab + ipilimumab Nivolumab + cisplatin/gemcitabine Platinum/gemcitabine Platinum/gemcitabine + placebo Co-primary endpoints: PFS and OS Final data collection date for primary endpoint: April 2018 Current accrual status: active, not recruiting Co-primary endpoints: PFS and OS (cisplatinineligible) Final data collection date for primary endpoint: April 2020 Current accrual status: recruiting ClinicalTrials.gov (NCT and NCT )
56 Current use of PD-L1/PD-1 inhibitors for metastatic urothelial cancer Non-muscle invasive bladder cancer (NMIBC) Muscle-invasive bladder cancer (MIBC) Metastatic urothelial cancer Low-grade High-grade Neoadjuvant Adjuvant Cisplatinineligible Cisplatineligible Cisplatinrefractory BCG-refractory Maintenance Figure adapted from Fakhrejahani et al. Curr Opin Urol 2015
57 Ongoing phase III studies of adjuvant PD-L1 inhibitors IMvigor010 (NCT ) Patients with high-risk bladder or upper tract muscle-invasive UC a Tumour stage If prior neoadjuvant chemotherapy: ypt2-t4a or ypn+ (ypt2-4 or ypn+ for UTUC) In no prior neoadjuvant chemotherapy: pt3-t4a or pn+ (pt3-4 or pn+ for UTUC) If no prior neoadjuvant chemotherapy, patients must be ineligible for or have refused adjuvant cisplatin chemotherapy Radical surgical resection within previous 14 weeks with no residual disease No prior adjuvant therapy ECOG PS 0 2 N=700 b [ R TECENTRIQ No crossover permitted Observation Recurrence/ survival follow-up Primary endpoint: DFS ClinicalTrials.gov (NCT )
58 Ongoing phase III studies of adjuvant PD-L1 inhibitors CheckMate 274 (NCT ) Invasive UC at high risk of recurrence originating in the bladder, ureter or renal pelvis Radical surgical resection (e.g. radical cystectomy) N=640 Co-primary endpoints: DFS in patients with tumours expressing 1% PD-L1 and in all randomised patients R Nivolumab Placebo AMBASSADOR (NCT ) Histologically confirmed muscle-invasive UC of the bladder or upper tract Neoadjuvant chemotherapy and pathologic stage at surgical resection is pt2 and/or N+ OR Patients who are not cisplatin-eligible OR Patients that decline adjuvant cisplatin-based or other systemic Radical surgical resection N=739 Co-primary endpoints: DFS and OS R Pembrolizumab Observation ClinicalTrials.gov (NCT and NCT )
59 Phase II neoadjuvant: ABACUS trial Powles T, et al. ASCO 2018
60 Phase II neoadjuvant: PURE-01 trial Powles T, et al. ASCO 2018
61 Current use of PD-L1/PD-1 inhibitors for metastatic urothelial cancer Non-muscle invasive bladder cancer (NMIBC) Muscle-invasive bladder cancer (MIBC) Metastatic urothelial cancer Low-grade High-grade Neoadjuvant Adjuvant Cisplatinineligible Cisplatineligible Cisplatinrefractory BCG-refractory Maintenance Figure adapted from Fakhrejahani et al. Curr Opin Urol 2015
62 NMIBC: POTOMAC trial (Hospital Clinico San Carlos)
63
64
Updates in Immunotherapy for Urothelial Carcinoma
Updates in Immunotherapy for Urothelial Carcinoma Andrew J Armstrong MD ScM FACP DUA 2018 Copyright 2006 SciMed. Talk Outline Immunotherapy progress in 2017: 5 new approved PD-1/PD-L1 inhibitory agents
Urothelial Cancers- New Strategies. Sandy Srinivas.MD Stanford University
Urothelial Cancers- New Strategies Sandy Srinivas.MD Stanford University Relevant financial relationships in the past twelve months by presenter or spouse/partner. Consultant: Genentech, Astra Zeneca The
A Giant Leap in the Treatment Options for Advanced Bladder Cancer
A Giant Leap in the Treatment Options for Advanced Bladder Cancer Yohann Loriot, MD, PhD Department of Cancer Medicine & INSERM U981 Gustave Roussy Villejuif, France Clinical Features of Bladder Cancer
The Rationale for Immunotherapy as an Adjuvant Treatment for Locally Advanced BC
The Rationale for Immunotherapy as an Adjuvant Treatment for Locally Advanced BC Seth P. Lerner, MD, FACS Professor, Scott Department of Urology Beth and Dave Swalm Chair in Urologic Oncology Baylor College
Largos Supervivientes, Tenemos datos?
Largos Supervivientes, Tenemos datos? Javier Puente, MD, PhD Medical Oncology Department. Hospital Clinico San Carlos Associate Professor of Medicine. Complutense University of Madrid. Summary Snapshot
Indication for- and timing of cytoreductive nephrectomy Kidney- and bladder cancer: Immunotherapy
Indication for- and timing of cytoreductive nephrectomy Kidney- and bladder cancer: Immunotherapy Axel Bex, MD, PhD The Netherlands Cancer Institute Oslo, September 4, 2018 Financial and Other Disclosures
Genomics and Genetics in BC: Precise selection for chemotherapy and Immunotherapy. Raanan Berger MD PhD Sheba Medical Center, Israel
Genomics and Genetics in BC: Precise selection for chemotherapy and Immunotherapy Raanan Berger MD PhD Sheba Medical Center, Israel Disclosures Honoraria, Ad board BMS, MSD, Pfizer, Astra Zeneca, Bayer,
Advanced Bladder Cancer: Check Mate or Check Point Inhibitors
Advanced Bladder Cancer: Check Mate or Check Point Inhibitors Daniel P Petrylak, MD Professor of Medicine and Urology Director, GU Translational Working Group Co Director, Signal Transduction Program Smilow
Urothelial Carcinoma Highlights
Urothelial Carcinoma Highlights Andrea Necchi Fondazione IRCCS Istituto Nazionale dei Tumori, Milano European Association of Urology Research Foundation Disclosures Consulting or Advisory Role: Company:
AVANCES EN EL TRATAMIENTO DE PRIMERA LINEA EN EL CANCER DE VEJIGA AVANZADO
AVANCES EN EL TRATAMIENTO DE PRIMERA LINEA EN EL CANCER DE VEJIGA AVANZADO Montse Domènech Althaia, Xarxa Assistencial i Universitària Manresa Urothelial Cancer Therapeutics FDA approved drugs for bladder
Optimizing treatment for metastatic bladder cancer in chemotherapy-resistant urothelial carcinoma. Moran Gadot M.D SHEBA Medical Center ISRAEL
Optimizing treatment for metastatic bladder cancer in chemotherapy-resistant urothelial carcinoma Moran Gadot M.D SHEBA Medical Center ISRAEL Disclosures none All (eligible) patients should get chemotherapy
Approved checkpoint inhibitors in bladder cancer: which drug should be used when?
788310TAM0010.1177/1758835918788310Therapeutic Advances in Medical OncologyP Ghatalia, M Zibelman research-article20182018 Therapeutic Advances in Medical Oncology Review Approved checkpoint inhibitors
Integrating Immunotherapy into Urologic Oncology: The New Urothelial Cancer Paradigm
Immunotherapy in Urothelial Cancer: Where are We Now & Where are We Going? Arjun Balar, MD Director of Genitourinary Medical Oncology Program NYU Langone Medical Center New York, NY Bladder Cancer Therapeutic
Neoplasie uroteliali 2017 Highlights. Andrea Necchi Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
Neoplasie uroteliali 2017 Highlights Andrea Necchi Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy Disclosures Consulting or Advisory Role: Company: Roche, Bayer, Merck & Co. Inc., Astra
Disclosure. Astellas. Research funding. Advisory board (to institute) Roche/Genentech Astra Zeneca/Medimmune Astellas
Disclosure Activity Company Research funding Advisory board (to institute) Astellas Roche/Genentech Astra Zeneca/Medimmune Astellas Immunotherapy for urothelial cell carcinoma A NEW HOPE Michiel van der
THE SEARCH FOR BIOMARKERS IN BLADDER CANCER
THE SEARCH FOR BIOMARKERS IN BLADDER CANCER CDDP and IO WORLD ALEJO RODRÍGUEZ-VIDA MD PhD Consultant Medical Oncologist Associate Professor Hospital del Mar, Barcelona November 23 rd 2018 DISCLOSURE OF
Metastatic Bladder Cancer: Immunotherapy. Joaquim Bellmunt, MD PhD Associate Professor of Medicine Harvard Medical School PSMAR-IMIM
Metastatic Bladder Cancer: mmunotherapy Joaquim Bellmunt, MD PhD Associate Professor of Medicine Harvard Medical School PSMAR-MM September 19 th, 2018 Disclosures Advisory role: Genentech, Merck, Pfizer,
UROTHELIAL CELL CANCER
UROTHELIAL CELL CANCER Indications and regimens for neoadjuvant systemic treatment Astrid A. M. van der Veldt, MD, PhD, medical oncologist Department of Medical Oncology Erasmus Medical Center Cancer Institute
Emerging Role of Immunotherapy in Advanced Urothelial Carcinoma
Current Oncology Reports (2018) 20:48 https://doi.org/10.1007/s11912-018-0693-y GENITOURINARY CANCERS (DP PETRYLAK AND JW KIM, SECTION EDITORS) Emerging Role of Immunotherapy in Advanced Urothelial Carcinoma
I Tumori della Vescica Inquadramento clinico Roberto Sabbatini Azienda Ospedaliero Universitaria Policlinico di Modena
I Tumori della Vescica Inquadramento clinico Roberto Sabbatini Azienda Ospedaliero Universitaria Policlinico di Modena XII Corso di aggiornamento AIRTUM per operatori dei Registri Tumori Reggio Emilia
Challenges in systemic treatment for metastatic bladder cancer. Phichai Chansriwong, MD Ramathibodi Hospital, Mahidol University
Challenges in systemic treatment for metastatic bladder cancer Phichai Chansriwong, MD Ramathibodi Hospital, Mahidol University OS PCG 15.8 vs GC 12.7 NS Cisplatin ineligible Second-line chemotherapy
Prostate cancer Management of metastatic castration sensitive cancer
18 th Annual Advances in Oncology - 2017 Prostate cancer Management of metastatic castration sensitive cancer Urothelial carcinoma Non-muscle invasive urothelial carcinoma Updates in metastatic urothelial
Exploring New Strategies in Bladder Cancer
Exploring New Strategies in Bladder Cancer Daniel P. Petrylak, MD Professor of Medicine and Urology Director, Genitourinary Translational Working Group Co-Director, Signal Transduction Program Smilow Cancer
Immunotherapy for Genitourinary Cancers
Immunotherapy for Genitourinary Cancers Susan F. Slovin, MD, PhD Genitourinary Oncology Service Sidney Kimmel Center for Prostate and Urologic Cancers Memorial Sloan Kettering Cancer Center New York, New
Checkpoint Inibitors for Bladder Cancer
Checkpoint Inibitors for Bladder Cancer Daniel P. Petrylak, MD Professor of Medicine and Urology Director, GU Translational Working Group Co Director, Signal Transduction Program Smilow Cancer Center,
Treatment of muscle invasive bladder cancer. ie: pt2. N. Mottet
Treatment of muscle invasive bladder cancer ie: pt2 N. Mottet Disclosures Astellas BMS Pierre Fabre Sanofi MIBC: really undertreated 28 691 MIBC in the US (national database). Gray Eur Urol 2013 Patients
Treatment of Advanced Bladder Cancer, Where We've Been and How to Move Forward
Treatment of Advanced Bladder Cancer, Where We've Been and How to Move Forward Maha Hussain, MD, FACP Professor of Medicine & Urology Co-Leader Prostate/GU Oncology Program Associate Director for Clinical
Urinary Bladder Cancer
Fellow GU Lecture Series, 2018 Urinary Bladder Cancer Asit Paul, MD, PhD 01/31/2018 Overview Non-muscle invasive bladder cancer Muscle invasive bladder cancer Bladder sparing chemo-radiation therapy T4b
Enterprise Interest Lecture 9º Personalized Healthcare in Oncology sponsored by Roche, Lisbon 2017 Bladder Diagnostic Advisory Board Invitation
Enterprise Interest Lecture 9º Personalized Healthcare in Oncology sponsored by Roche, Lisbon 2017 Bladder Diagnostic Advisory Board Invitation sponsored by Astra-Zeneca, London 2017 SPEC-02 ESP/ESMO PD-L1
Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr.
Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr. Diretor de Onco-Hematologia Hospital BP, A Beneficência Portuguesa Non-Small Cell Lung Cancer PD-1/PD-L1 Inhibitors in second-line therapy
Metastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian
Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in
Conversations in Oncology. November Kerry Hotel Pudong, Shanghai China
Conversations in Oncology November 12-13 Kerry Hotel Pudong, Shanghai China Immunotherapy of Lung Cancer Professor Caicun Zhou All materials are for scientific exchanges. Afatinib and nintedanib are not
La realidad de la inmunoterapia en el tratamiento de 1ª y 2ª línea del cáncer de vejiga
La realidad de la inmunoterapia en el tratamiento de 1ª y 2ª línea del cáncer de vejiga Daniel Castellano Oncología Médica. Unidad de Tumores Genito-Urinarios Hospital Universitario 12 de Octubre. I +
Out of 129 patients with NSCLC treated with Nivolumab in a phase I trial, the OS rate at 5-y was about 16 %, clearly higher than historical rates.
6th Meeting on external quality assessment in molecular pathology, Naples, May 12-13, 2017 Overview of clinical development of checkpoint inhibitors in solid tumors Pr Jaafar BENNOUNA University of Nantes
PD1/PDL-1 Inhibitors: Emerging Hope for Bladder Cancer
Journal of Cancer Treatment and Research 2017; 5(5): 71-80 http://www.sciencepublishinggroup.com/j/jctr doi: 10.11648/j.jctr.20170505.11 ISSN: 2376-7782 (Print); ISSN: 2376-7790 (Online) PD1/PDL-1 Inhibitors:
Immunotherapy for the Treatment of Head and Neck Cancers. Robert F. Taylor, MD Aurora Health Care
Immunotherapy for the Treatment of Head and Neck Cancers Robert F. Taylor, MD Aurora Health Care Disclosures No relevant financial relationships to disclose I will be discussing non-fda approved indications
IMMUNE CHECKPOINT THERAPY FOR GENITOURINARY CANCERS: KIDNEY CANCER AND TRANSITIONAL CELL CARCINOMA
IMMUNE CHECKPOINT THERAPY FOR GENITOURINARY CANCERS: KIDNEY CANCER AND TRANSITIONAL CELL CARCINOMA Kathleen Mahoney, M.D., Ph.D. Instructor of Medicine, Harvard Medical School Attending, Beth Israel Deaconess
Immunoterapia nella malata avanzata. Daniele Raggi Fondazione IRCCS Isttuto Nazionale dei Tumori, Milano
Immunoterapia nella malata avanzata Daniele Raggi Fondazione IRCCS Isttuto Nazionale dei Tumori, Milano Five checkpoint inhibitors now approved for UC! BCG Atezolizumab (US/EU) (2L) Atezolizumab (US/EU)
NOVÉ MOŽNOSTI LÉČBY NÁDORŮ MOČOVÉHO MĚCHÝŘE A JEJICH ZAŘAZENÍ DO ALGORITMU LÉČBY. Jindřich Fínek LF UK a FN Plzeň
NOVÉ MOŽNOSTI LÉČBY NÁDORŮ MOČOVÉHO MĚCHÝŘE A JEJICH ZAŘAZENÍ DO ALGORITMU LÉČBY Jindřich Fínek LF UK a FN Plzeň 1 KARCINOM MOČOVÉHO MĚCHÝŘE INCIDENCE A MORTALITA 2 KARCINOM MOČOVÉHO MĚCHÝŘE ZASTOUPENÍ
Immune checkpoint inhibitors in NSCLC
1 Immune checkpoint inhibitors in NSCLC Rolf Stahel University Hospital of Zürich Zürich, November 3, 2017 2 What can we learn from the clinical experience of second line immunotherapy of advanced NSCLC?
Immunotherapy for the Treatment of Kidney and Bladder Cancer
Immunotherapy for the Treatment of Kidney and Bladder Cancer Alan J. Koletsky, MD Genitourinary Cancer Research Program, Lynn Cancer Institute Clinical Asistant Professor of Biomedical Science The Charles
Immunotherapy in the clinic. Lung Cancer. Marga Majem 20 octubre 2017
Immunotherapy in the clinic. Lung Cancer Marga Majem 20 octubre 2017 mmajem@santpau.cat Immunotherapy in the clinic. Lung Cancer Agenda Where we come from? Immunotherapy in Second line Immunotherapy in
Immunotherapy, an exciting era!!
Immunotherapy, an exciting era!! Yousef Zakharia MD University of Iowa and Holden Comprehensive Cancer Center Alliance Meeting, Chicago November 2016 Presentation Objectives l General approach to immunotherapy
Immunotherapy for the Treatment of Head and Neck Cancers. Barbara Burtness, MD Yale University
Immunotherapy for the Treatment of Head and Neck Cancers Barbara Burtness, MD Yale University Disclosures AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim, Bristol-Myers Squibb, Merck & Co., Inc.,
Cancer Drugs Fund. Managed Access Agreement. Atezolizumab for untreated metastatic urothelial cancer where cisplatin is unsuitable
Cancer Drugs Fund Managed Access Agreement Atezolizumab for untreated metastatic urothelial cancer where cisplatin is unsuitable NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Cancer Drugs Fund Data
La revolución de la inmunoterapia: dónde la posicionamos? Javier Puente, MD, PhD
La revolución de la inmunoterapia: dónde la posicionamos? Javier Puente, MD, PhD Hospital Universitario Clinico San Carlos Medical Oncology Department Thoracic & Urological Cancer Unit Complutense University
INMUNOTERAPIA I. Dra. Virginia Calvo
INMUNOTERAPIA I Dra. Virginia Calvo LBA62. Health-related quality of life (HRQoL) for Pembrolizumab or placebo plus Carboplatin and Paclitaxel or nab-paclitaxel in patients with metastatic squamous NSCLC:
Bristol-Myers Squibb. Request for Educational Activity (RFE)
Bristol-Myers Squibb Independent Medical Education Request for Educational Activity (RFE) Date RFP Code Therapeutic Area Areas of Interest Educational Design Intended Audience Budget Accreditation Geographic
Weitere Kombinationspartner der Immunotherapie
1 Weitere Kombinationspartner der Immunotherapie Rolf Stahel University Hospital of Zürich Zürich, 9.12.216 2 Immunotherapy in a multimodality approach NSCLC Advanced disease Checkpoint inhibitors for
Neoplasie uroteliali Posters & oral presentations
UPDATES and NEWS from the Genitourinary Cancers Symposium 3 Marzo 2017, Milano Neoplasie uroteliali Posters & oral presentations Cristina Masini Oncologia Medica IRCCS-Arcispedale S.Maria Nuova - Reggio
IMMUNE CHECKPOINT BLOCKADE IN UROTHELIAL CANCER
IMMUNE CHECKPOINT BLOCKADE IN UROTHELIAL CANCER Elizabeth R. Plimack MD MS Director, Genitourinary Clinical Research Associate Professor, Hematology/Oncology Fox Chase Cancer Center, Temple Health Neoadjuvant
RECENT DEVELOPMENTS in Muscle Invasive Bladder Cancer
RECENT DEVELOPMENTS in Muscle Invasive Bladder Cancer IX CIS and EURASIA ONCOLOGY and RADOLOGY CONGRESS, ONCOUROLOGY SESSION 16 June 2016 Richard E Greenberg, MD, FACS Chief Urologic Oncology, Fox Chase
Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma
Kamat et al. Journal for ImmunoTherapy of Cancer (2017) 5:68 DOI 10.1186/s40425-017-0271-0 POSITION ARTICLE AND GUIDELINES Society for Immunotherapy of Cancer consensus statement on immunotherapy for the
Immunotherapy for Breast Cancer. Aurelio B. Castrellon Medical Oncology Memorial Healthcare System
Immunotherapy for Breast Cancer Aurelio B. Castrellon Medical Oncology Memorial Healthcare System Conflicts Research support : Cascadian therapeutics, Puma biotechnology, Odonate therapeutics, Pfizer,
IMMUNOTHERAPY FOR GASTROINTESTINAL CANCERS
IMMUNOTHERAPY FOR GASTROINTESTINAL CANCERS Dr Elizabeth Smyth Cambridge University Hospitals NHS Foundation Trust ESMO Gastric Cancer Preceptorship Valencia 2018 DISCLOSURES Honoraria for advisory role
Post-ASCO Immunotherapy Highlights (Part 2): Biomarkers for Immunotherapy
Post-ASCO Immunotherapy Highlights (Part 2): Biomarkers for Immunotherapy Lee S. Schwartzberg, MD, FACP Chief, Division of Hematology Oncology; Professor of Medicine, The University of Tennessee; The West
Biomarkers for immunotherapy in bladder cancer: a moving target
Aggen and Drake Journal for ImmunoTherapy of Cancer (2017) 5:94 DOI 10.1186/s40425-017-0299-1 REVIEW Biomarkers for immunotherapy in bladder cancer: a moving target David H. Aggen * and Charles G. Drake
Challenging Genitourinary Tumors: What s New in 2017
Challenging Genitourinary Tumors: What s New in 2017 David J. Vaughn, MD Genitourinary Medical Oncology Professor Please note that some of the studies reported in this presentation were presented as an
Oral Communications & Posters
Carcinoma uroteliale: Current and future directions of treatment of Muscle-Invasive Bladder cancer/ Multimodality approach of bladder cancer Oral Communications & Posters CRISTINA MASINI Oncologia Medica
Immune Therapy in Clear Cell Ovarian Cancer (ITICC) Hal Hirte Canadian Cancer Clinical Trials Group
Immune Therapy in Clear Cell Ovarian Cancer (ITICC) Hal Hirte Canadian Cancer Clinical Trials Group Results of Phase II Study of Durvalumab and Tremelimumab in recurrent clear cell ovarian cancer Trial
Histology independent indications in Oncology
CHMP Oncology Working Party Workshop Histology independent indications in Oncology What have we learnt from the anti PD1- PDL1 story? J Camarero (CHMP alternate ES, OncWP) Disclaimers the views presented
Melanoma: Immune checkpoints
ESMO Preceptorship Programme Immuno-Oncology Siena, July 04-05, 2016 Melanoma: Immune checkpoints Michele Maio Medical Oncology and Immunotherapy-Department of Oncology University Hospital of Siena, Istituto
Plotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma
Pieter E. Postmus University of Liverpool Liverpool, UK Plotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma Disclosures Advisor Bristol-Myers Squibb AstraZeneca
NSCLC: immunotherapy as a first-line treatment. Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To)
NSCLC: immunotherapy as a first-line treatment Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To) The 800-pound gorilla Platinum-based chemotherapy is the SOC for 1st-line therapy in
R&D Conference Call. CHUGAI PHARMACEUTICAL CO., LTD. Department Manager of Oncology Lifecycle Management Dept. Megumi Uzu.
R&D Conference Call CHUGAI PHARMACEUTICAL CO., LTD. Department Manager of Oncology Lifecycle Management Dept. Megumi Uzu July 4, 2016 Forward-Looking Statements This presentation may include forward-looking
Highlights STOMACH CANCER
UPDATES and NEWS from the Gastrointestinal Cancers Symposium in San Francisco Roma, 10-11 Febbraio 2017 Highlights STOMACH CANCER Lorenzo Fornaro, MD Unit of Medical Oncology 2 Azienda Ospedaliero-Universitaria
General Information, efficacy and safety data
Horizon Scanning in Oncology Horizon Scanning in Oncology 23 rd Prioritization 2 nd quarter 2015 General Information, efficacy and safety data Eleen Rothschedl Anna Nachtnebel Priorisierung XXIII HSS Onkologie
Welcome and Introductions
Welcome and Introductions Ashish M. Kamat, MD, MBBS, FACS Professor of Urologic Oncology Wayne B. Duddlesten Professor of Cancer Research President, International Bladder Cancer Group (IBCG) University
Debaters For The Evening:
Your Debaters For The Evening: Current State of Immune Checkpoint Blockade in Selected Types of Solid Tumors Jeffery Weber, MD, PhD Naiyer A. Rizvi, MD Current State of ICI in Melanoma and Bladder Cancers
New Therapies in HCC Bruno Sangro Clínica Universidad de Navarra. IdISNA. CIBERehd. Pamplona, Spain
New Therapies in HCC Bruno Sangro Clínica Universidad de Navarra. IdISNA. CIBERehd. Pamplona, Spain PHC 2018 - www.aphc.info EASL-EORTC Guidelines EASL EORTC Guidelines. J Hepatol. 2012;56:908-43. Systemic
Disclosures. Immunotherapyin Head & NeckCancer. Actual landscape of systemic treatment in HNSCC. Head andneckcanceris an immunogeneic tumor
Immunotherapyin Head & NeckCancer Disclosures Astra-Zeneca/medimmune: clinical trial BMS: advisory board, clinical trial Merck: advisory board, clinical trial, research funding Carla van Herpen Medical
Il ruolo di PD-L1 (42%) tra la prima e la seconda linea di trattamento
Il ruolo di PD-L1 (42%) tra la prima e la seconda linea di trattamento Alessia Pochesci Divisione di Oncologia Toracica Istituto Europeo di Oncologia, Milano Tutor: Prof.ssa Silvia Novello Dott.ssa Chiara
Lung Cancer Immunotherapy
Lung Cancer Immunotherapy Luis E. Raez MD FACP FCCP Chief of Hematology/Oncology & Medical Director Memorial Cancer Institute/Memorial Health Care System Clinical Professor of Medicine Herbert Wertheim
Immunotherapy in non-small cell lung cancer
Immunotherapy in non-small cell lung cancer Geoffrey Peters and Thomas John Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia. Email: Geoffrey.peters@austin.org.au Abstract
News from ASCO. Niven Mehra, Medical Oncologist. Radboud UMC Institute of Cancer Research and The Royal Marsden Hospital
News from ASCO Niven Mehra, Medical Oncologist Radboud UMC Institute of Cancer Research and The Royal Marsden Hospital Disclosures Speaker fees: Merck, Bayer Advisory boards: Janssen-Cilag Research and
Neodjuvant chemotherapy
Neodjuvant chemotherapy Dr Robert Huddart Senior Lecturer and Honorary Consultant in Clinical Oncology Royal Marsden Hospital and Institute of Cancer Research Why consider neo-adjuvant chemotherapy? Loco-regional
Recent Advances in Lung Cancer: Updates from ASCO Updates from ESMO, AACR and ASCO
Recent Advances in Lung Cancer: Updates from ASCO 2018 Updates from ESMO, AACR and ASCO Charu Aggarwal, MD, MPH Assistant Professor of Medicine Division of Hematology-Oncology Abramson Cancer Center University
ESMO Preceptorship Breast Cancer. Giuseppe Curigliano MD, PhD Breast Cancer Program Division of Early Drug Development Istituto Europeo di Oncologia
ESMO Preceptorship Breast Cancer Giuseppe Curigliano MD, PhD Breast Cancer Program Division of Early Drug Development Istituto Europeo di Oncologia Outline Rational for immune-based therapy in BC How to
PERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER. Virginie Westeel Chest Disease Department University Hospital Besançon, France
PERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER Virginie Westeel Chest Disease Department University Hospital Besançon, France LEARNING OBJECTIVES 1. To understand the potential of perioperative
Tumori Genito-Urinari. Fabio Calabrò Oncologia Medica Azienda Ospedaliera San Camillo Forlanini
Tumori Genito-Urinari Fabio Calabrò Oncologia Medica Azienda Ospedaliera San Camillo Forlanini Prostate cancer treatment paradigm is evolving PROSTATE CANCER TREATMENT PARADIGMIS EVOLVING Non metatasticcrpc
Maintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse?
Maintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse? Mark A. Socinski, MD Professor of Medicine Multidisciplinary Thoracic Oncology Program Lineberger Comprehensive
Presentation Number: LBA18_PR. Lecture Time: 09:15-09:27. Speakers: Heinz-Josef J. Lenz (Los Angeles, US) Background
LBA18_PR - Durable Clinical Benefit With Nivolumab (NIVO) Plus Low-Dose Ipilimumab (IPI) as First-Line Therapy in Microsatellite Instability-High/Mismatch Repair Deficient (MSI-H/dMMR) Metastatic Colorectal
Immunotherapy in GU Cancers. Dr Ravindran Kanesvaran Medical Oncologist National Cancer Centre Singapore
Immunotherapy in GU Cancers Dr Ravindran Kanesvaran Medical Oncologist National Cancer Centre Singapore 1 Disclosures Speaker Bureau: Pfizer, J&J, Sanofi, Novartis, MSD Advisory Board/ Consultant: GSK,
Tratamiento adyuvante y neoadyuvante del cáncer renal en Xavier Garcia del Muro Solans Institut Català d Oncologia Hospitalet.
Tratamiento adyuvante y neoadyuvante del cáncer renal en 2017 Xavier Garcia del Muro Solans Institut Català d Oncologia Hospitalet. Barcelona Pronóstico del CR mediante un sistema integrado en 468 pts
Triple negative breast cancer -neoadjuvant and adjuvant systemic therapy
Triple negative breast cancer -neoadjuvant and adjuvant systemic therapy Sung-Bae Kim, MD, PhD Department of Oncology Asan Medical Center University of Ulsan College of Medicine Seoul, Korea DISCLOSURE
Roche provides update on phase III study of TECENTRIQ (atezolizumab) in people with previously treated advanced bladder cancer
Media Release Basel, 10 May 2017 Roche provides update on phase III study of TECENTRIQ (atezolizumab) in people with previously treated advanced bladder cancer IMvigor211 study did not meet its primary
Current Issues in Checkpoint Immunotherapy for NSCLC: A Perspective from January 2018
Current Issues in Checkpoint Immunotherapy for NSCLC: A Perspective from January 2018 David R. Gandara, MD University of California Davis Comprehensive Cancer Center Disclosures Research Grants: AstraZeneca/Medi,
Biomarkers in Imunotherapy: RNA Signatures as predictive biomarker
Biomarkers in Imunotherapy: RNA Signatures as predictive biomarker Joan Carles, MD PhD Director GU, CNS and Sarcoma Program Department of Medical Oncology Vall d'hebron University Hospital Outline Introduction
Update on the development of immune checkpoint inhibitors
Update on the development of immune checkpoint inhibitors Jean-Pascal Machiels Department of Medical Oncology Laboratory of Medical Oncology Cliniques universitaires Saint-Luc Université catholique de
Immunotherapy for the Treatment of Melanoma. Marlana Orloff, MD Thomas Jefferson University Hospital
Immunotherapy for the Treatment of Melanoma Marlana Orloff, MD Thomas Jefferson University Hospital Disclosures Immunocore and Castle Biosciences, Consulting Fees I will be discussing non-fda approved
2019 ASCO Genitourinary Cancers Symposium
2019 ASCO Genitourinary Cancers Symposium Analyst Call February 15, 2019 This presentation includes forward-looking statements regarding Nektar s proprietary drug candidates, the timing of the start and
Checkpoint inhibitors in the treatment of urological malignancies
Review Checkpoint inhibitors in the treatment of urological malignancies Lazar S Popovic, 1,2 Gorana Matovina-Brko, 1,2 Maja Popovic 1,2 To cite: Popovic LS, Matovina-Brko G, Popovic M. Checkpoint inhibitors
Practice changing studies in lung cancer 2017
1 Practice changing studies in lung cancer 2017 Rolf Stahel University Hospital of Zürich Cape Town, February 16, 2018 DISCLOSURE OF INTEREST Consultant or Advisory Role in the last two years I have received
Developping the next generation of studies in RCC
Developping the next generation of studies in RCC Bernard Escudier Institut Gustave Roussy Villejuif, France Disclosure Information Advisory/Consultancy Role Pfizer, Exelixis, Novartis, BMS, Bayer, Roche,
Squamous Cell Carcinoma Standard and Novel Targets.
Squamous Cell Carcinoma Standard and Novel Targets. Mohamed K. Mohamed, MD, PhD Director of Thoracic Oncology Cone Health Cancer Center Greensboro, NC 1 Mohamed Mohamed, MD, PhD Squamous Cell Carcinoma:
Advances in Breast Cancer Therapeutics in the Adjuvant and Metastatic Settings. Eve Rodler, MD University of California at Davis October 2016
Advances in Breast Cancer Therapeutics in the Adjuvant and Metastatic Settings Eve Rodler, MD University of California at Davis October 2016 17th Annual Advances in Oncology September 30-October 1, 2016
MEETING SUMMARY ESMO 2018, Munich, Germany. Dr. Jenny Seligmann University of Leeds, UK HIGHLIGHTS ON COLORECTAL CANCER
MEETING SUMMARY ESMO 2018, Munich, Germany Dr. Jenny Seligmann University of Leeds, UK HIGHLIGHTS ON COLORECTAL CANCER DISCLAIMER Please note: The views expressed within this presentation are the personal
Renal Cell Carcinoma: Systemic Therapy Progress and Promise
Renal Cell Carcinoma: Systemic Therapy Progress and Promise Michael B. Atkins, M.D. Deputy Director, Lombardi Comprehensive Cancer Ctr Georgetown University Medical Center Everolimus Rini, Campbell, Escudier.
Immunoterapia di 1 linea Evidenze e Prospettive Future
Immunoterapia di 1 linea Evidenze e Prospettive Future Sara Pilotto Oncologia Medica, Dipart. di Medicina, Università di Verona, A.O.U.I. Verona sara.pilotto@univr.it Negrar, 30 ottobre 2018 Disclosures
Sergio Vázquez Estévez Sº Oncoloxía Médica Hospital Universitario Lucus Augusti. Lugo
PAPEL ACTUAL Y DE FUTURO DE LA INMUNOTERAPIA EN EL ABORDAJE TERAPÉUTICO DEL CÁNCER DE VEJIGA Y OTRAS VÍAS DE PROGRESO. CÓMO SELECCIONAR PACIENTES PARA INMUNOTERAPIA O PARA QUIMIOTERAPIA. Sergio Vázquez